← All Barinthus Biotherapeutics PLC filings

Barinthus Biotherapeutics PLC Schedule 13G passive stakes

Filed when an investor crosses five percent without intending to seek control — the passive counterpart to a 13D.

NASDAQ
BRNS
Barinthus Biotherapeutics PLC
SCHEDULE 13G/A: Frank W. Cawood Discloses 8.4% Stake in Barinthus Biotherapeutics Plc
Frank W. Cawood has filed an amended Schedule 13G, disclosing a beneficial ownership of 8.4% of Barinthus Biotherapeutics Plc's American Depositary Shares as of December 31, 2024.